Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Breast Neoplasms 108Endometrial Neoplasms 16Polycystic Ovary Syndrome 9Neoplasm Metastasis 9Ovarian Neoplasms 7Neoplasms 7Advanced Breast Cancer 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Fallopian Tube Neoplasms 4Recurrence 3Infertility 3Carcinoma, Intraductal, Noninfiltrating 3Breast Neoplasms, Male 3Squamous Cell Carcinoma of Head and Neck 2Progesterone Resistance 2Neoplasms by Site 2Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Neoplasms 2HR+/HER2- Breast Cancer 2Estrogen Receptor-positive Breast Cancer 2Endometrial Hyperplasia 2Cystadenocarcinoma, Serous 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Breast Cancer Metastatic 2Breast Cancer Female 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Small Cell Lung Carcinoma 1

Interventions

exemestane 1Leuprolide 1Letrozole 1Holistic Health 1Goserelin 1Gonadotropin-Releasing Hormone 1Bupropion 1Aromatase Inhibitors 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sexual Dysfunctions, Psychological × Letrozole × 1 year × Clear all
NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡